Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,470.00
(
-1.06%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,712.99
(
0.28%
)
News Focus
News Focus
Post# of 257265
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 170499

Saturday, 03/04/2017 3:48:47 PM

Saturday, March 04, 2017 3:48:47 PM

Post# of 257265
India’s Supreme Court rules in favor of MYL/Biocon re Herceptin FoB:

http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/delhi-hc-gives-biocon-mylan-green-light-to-market-blockbuster-biosimilar-for-three-cancers/articleshow/57451618.cms

The Court made two concessions: i) MYL/Biocon can now include Roche’s data for branded Herceptin in the FoB product label; and ii) the FoB is approved for all three of branded Herceptin’s indications.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today